IASO Bio is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and autoimmune diseases. Leveraging its proprietary fully human antibody discovery platform (IMARS), high-throughput chimeric antigen receptor T-cell (CAR-T) drug screening platform, and proprietary manufacturing processes, IASO Bio is developing a rich clinical-stage pipeline of multiple autologous and allogeneic CAR-T and biologics product candidates.

The term expanded access (sometimes referred to as “compassionate use” or “pre-approval access”) is used to describe treatment with an investigational product for a patient with a serious or immediately life-threatening illness when there are no comparable or satisfactory alternative treatments available and the patient is ineligible or unable to participate in a clinical trial. 

IASO Bio is working to demonstrate the safety and effectiveness of several immuno-oncology products. We are conducting thoughtfully designed and robust clinical trial programs in order to obtain the global regulatory approvals needed to make these therapies widely available to the patients that need them around the world. We are currently unable to offer expanded access to our immuno-oncology therapies and we believe that participation in one of our clinical trials is the best way for patients to access our investigational therapies.

As authorized by the 21st Century Cures Act. IASO Bio may revise this Expanded Access Policy at any time.